Molecular diagnostics and response
| Gene . | No. of individuals with mutations . | No. (%) CR/CRi after 3 cycles . |
|---|---|---|
| DNMT3A | 46 | 18 (39) |
| TET2 | 36 | 10 (28) |
| ASXL1 | 35 | 7 (20) |
| SRSF2 | 34 | 8 (24) |
| RUNX1 | 32 | 9 (28) |
| TP53 | 27 | 15 (56) |
| IDH2 | 23 | 4 (17) |
| NRAS | 21 | 8 (38) |
| NPM1 | 19 | 5 (26) |
| STAG2 | 17 | 2 (12) |
| U2AF1 | 15 | 8 (53) |
| SF3B1 | 15 | 6 (40) |
| JAK2 | 12 | 6 (50) |
| BCOR | 12 | 5 (42) |
| EZH2 | 11 | 2 (18) |
| CEBPA | 10 | 2 (20) |
| FLT3 | 10 | 4 (40) |
| Gene . | No. of individuals with mutations . | No. (%) CR/CRi after 3 cycles . |
|---|---|---|
| DNMT3A | 46 | 18 (39) |
| TET2 | 36 | 10 (28) |
| ASXL1 | 35 | 7 (20) |
| SRSF2 | 34 | 8 (24) |
| RUNX1 | 32 | 9 (28) |
| TP53 | 27 | 15 (56) |
| IDH2 | 23 | 4 (17) |
| NRAS | 21 | 8 (38) |
| NPM1 | 19 | 5 (26) |
| STAG2 | 17 | 2 (12) |
| U2AF1 | 15 | 8 (53) |
| SF3B1 | 15 | 6 (40) |
| JAK2 | 12 | 6 (50) |
| BCOR | 12 | 5 (42) |
| EZH2 | 11 | 2 (18) |
| CEBPA | 10 | 2 (20) |
| FLT3 | 10 | 4 (40) |
Data from 140 patients with available extensive molecular analyses are considered.